Clinical experience with fosphenytoin in children

Journal of Child Neurology

Volumn 13, Issue SUPPL. 1, 1998, Pages

  Morton, Lawrence Daniel ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; DIAZEPAM; FOSPHENYTOIN SODIUM; PARALDEHYDE; PENTOBARBITAL; PHENYTOIN; VALPROIC ACID;

ADOLESCENT; ANTICONVULSANT THERAPY; ARTICLE; ATAXIA; CHILD; CHILDHOOD DISEASE; DRUG INDUCED DISEASE; DRUG SAFETY; EDEMA; EPILEPSY; EPILEPTIC STATE; ERYTHEMA; HUMAN; INFANT; INJECTION SITE; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; NEWBORN; NYSTAGMUS; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PRURITUS; RECTAL DRUG ADMINISTRATION; SEIZURE;

EID: 0031720206     PISSN: 08830738     EISSN: None     Source Type: Journal    
DOI: 10.1177/0883073898013001061     Document Type: Article

References (4)

1. Allen FH Jr, Runge JW, Legarda S, et al: Safety, tolerance and pharmacokinetics of intravenous fosphenytoin (Cerebyx) in status epilepticus, abstract. Epilepsia 1995;36(Suppl 4):90.
2. Morton LD, Pellock JM, Gilman JT, et al: Fosphenytoin pharmacokinetics and safety in pediatric patients, abstract. Ann Neurol 1997;42:504.
3. Morton LD, Pellock JM, Marin BL, et al: Fosphenytoin safety and pharmacokinetics in children, abstract. Epilepsia 1997;38(Suppl 8):194.
4. Pellock JM, DeLorenzo RJ: Status epilepticus, in Porter RJ, Chadwick D (eds): The Epilepsies 2. Oxford, UK, Butterworth-Heinemann, 1997, pp 267-287.